A Phase II Trial of Gefitinib (Iressa®) Plus Celecoxib (Celebrex®) in Chemotherapy-naïve Patients with Stage IIIb/IV Non-Small Cell Lung Cancer (NSCLC)

Abstracts/Posters/Presentations:

• A. Agarwala, L. Einhorn, W. Fisher, D. Bruetman, J. McClean, D. Taber, M. Titzer, B.Juliar, T. Breen, N. Hanna. Gefitinib plus Celecoxib in Chemotherapy-Naïve Patients with Stage IIIB/IV Non-small Cell Lung Cancer (NSCLC): A Phase II Study from the Hoosier Oncology Group LUN02-50. Presented as part of the Scientific Program in the Lung Cancer General Poster Session 2006 Annual Meeting of the American Society of Clinical Oncology. June 2-6, 2006, Atlanta, Georgia

Manuscripts/Articles:

• Moore AM, Einhorn LH, Estes D, Govindan R, Axelson J, Vinson J, Breen TE, Yu M, Hanna NH. Gefitinib in patients with chemo-sensitive and chemo-refractory relapsed small cell cancers: a Hoosier Oncology Group phase II trial. Lung Cancer. 2006 Apr;52(1):93-7. Epub 2006 Feb 20. See abstract.
• Agarwala A, Fisher W, Bruetman D, McClean J, Taber D, Titzer M, Juliar B, Yu M, Breen T, Einhorn LH, Hanna N. Gefitinib plus celecoxib in chemotherapy-naïve patients with stage IIIB/IV non-small cell lung cancer: a phase II study from the Hoosier Oncology Group. Thorac Oncol. 2008 Apr;3(4):374-9. doi: 10.1097/JTO.0b013e3181693869. See abstract.